scholarly journals ANTICOAGULATION COMPLICATIONS IN A PATIENT WITH PRIOR CEREBRAL VENOUS THROMBOSIS

2015 ◽  
Vol 14 (2) ◽  
pp. 101-104
Author(s):  
Ioana Cociasu ◽  
◽  
Irene Davidescu ◽  
Ioan Buraga ◽  
Bogdan Ovidiu Popescu ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Acute Phase ◽  
Cerebral Venous Thrombosis ◽  
Rare Form

Cerebral venous thrombosis is a rare form of stroke treated with anticoagulant compounds both in the acute phase as well as in long term. We present the case of a 56 year old female that suffered two different forms of stroke in 2 years.

Dehydration Status Predicts Short-Term and Long-Term Outcomes in Patients with Cerebral Venous Thrombosis

2018 ◽  
Vol 30 (2) ◽  
pp. 478-483 ◽  
Author(s):  
Kai Liu ◽  
Lulu Pei ◽  
Yuan Gao ◽  
Lu Zhao ◽  
Hui Fang ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Cerebral Venous Thrombosis ◽  
Long Term Outcomes ◽  
Short Term

scholarly journals A young woman with headache and seizures

2013 ◽  
pp. 25-29
Author(s):  
A.M. Pizzini ◽  
M. Silingardi ◽  
I. Iori
Keyword(s):  
Venous Thrombosis ◽  
Cerebral Venous Thrombosis ◽  
Mr Angiography ◽  
Sinus Thrombosis ◽  
Factor V Leiden ◽  
Transverse Sinus ◽  
Acute Onset ◽  
Factor V ◽  
Neuroimaging Techniques

CASE REPORT We describe a 31 year-old woman with headache and acute onset of seizures. Medical history and physical examination were unremarkable. She has been on therapy with oral contraceptives for many years for dysmenorrhea. A CT scan was negative, but MRI and MR-angiography showed left transverse sinus thrombosis. Screening for thrombophilia revealed hyperhomocysteinemia and Factor V Leiden heterozigousity. The patient received unfractionated heparin, followed by long-term anticoagulation with warfarin (INR 2-3). CONCLUSIONS Cerebral venous thrombosis is a rare cerebrovascular disorder, frequently in young adult (about 75% are women). The diagnosis might be difficult with consequent high long-term morbidity and mortality rate. New neuroimaging techniques (MRI and MR-angiography) and more effective treatment (anticoagulation and endovascular thrombolysis) have improved the prognosis and the natural history. The risk factors, the clinical presentation, the diagnostic evaluation and the management of cerebral venous thrombosis are reviewed.

Long-term Prognosis in Cerebral Venous Thrombosis

Stroke ◽  
1996 ◽  
Vol 27 (2) ◽  
pp. 243-246 ◽  
Author(s):  
Maurice Preter ◽  
Christophe Tzourio ◽  
Alain Ameri ◽  
Marie-Germaine Bousser
Keyword(s):  
Venous Thrombosis ◽  
Cerebral Venous Thrombosis ◽  
Long Term Prognosis

scholarly journals CEREBRAL VENOUS THROMBOSIS SECONDARY TO SARS-COV-2 INFECTION

2021 ◽  
Vol 5 (4) ◽  
Author(s):  
Heng Gee Lee ◽  
Heng Gee Lee ◽  
Heng Gee Lee ◽  
Heng Gee Lee
Keyword(s):  
Venous Thrombosis ◽  
Neurological Deficit ◽  
Cerebral Venous Thrombosis ◽  
Onset Seizure ◽  
Rare Form ◽  
Focal Neurological Deficit ◽  
Younger Women ◽  
First Onset

Cerebral venous thrombosis (CVT) is a relatively rare form of neurovascular emergency, and may present as headache, seizure, or focal neurological deficit. It typically has a higher occurrence in younger women. Recently, there are increasingly cases of CVTreported in association with COVID-19, which fall outside the typical demographics, suggesting a hyper-coagulable state attributable to COVID-19. Here, we present a case of CVTin a young gentleman with concomitant COVID-19, who presented with first-onset seizure.

Abstract 3920: Epilepsy as a Long-Term Complication After Cerebral Venous Thrombosis

Stroke ◽  
2012 ◽  
Vol 43 (suppl_1) ◽  
Author(s):  
Carlos Cantu-Brito ◽  
Erwin Chiquete ◽  
Antonio Arauz ◽  
Marlon Merloz-Benitez
Keyword(s):  
Risk Factors ◽  
Venous Thrombosis ◽  
Cerebral Venous Thrombosis ◽  
Clinical Presentation ◽  
Thrombotic Event ◽  
Long Run ◽  
Increased Risk ◽  
Long Term Follow Up

Background. Seizures is a very common clinical presentation of cerebral venous thrombosis (CVT); however, little is known about the future risk of epilepsy in patients suffering CVT. Our objective was to analyze risk factors for epilepsy in a long-term follow-up after CVT. Methods. This is a cohort descriptive study of consecutive non-selected patients with acute cerebrovascular disease, systematically registered from 1986 to 2010 in a third-level referral center of Mexico City. Here we analyzed 340 patients who survived the first 6 months after CVT, who were not epileptic at baseline and for whom complete long-term information on neurological outcome was available. Results. Seizures occurred in 183 (54%) patients, in 26% of them as a clinical presentation and 74% at some point during follow-up. Focal motor seizures occurred in 6.5%, secondary generalized focal seizures in 13.8% and generalized tonic-clonic seizures in 22.4%. Status epilepticus occurred in 13 (7%) cases. In all, during a median follow-up of 28 months (range 2 to 288 months), epilepsy was present in 14.7% (27.3% of those who presented seizures). In a multivariate analysis adjusted for multiple confounders, risk factors associated with an increased risk of epilepsy during follow-up were presenting seizures as a clinical presentation [odds ratio (OR): 4.32, 95% confidence interval (CI): 2.20-8.48], pregnancy and puerperium (OR: 2.03, 95% CI: 1.11-3.71) and thrombosis of the longitudinal sinus (OR: 1.86, 95% CI: 1.01-3.41). Conclusion. Seizures are common at CVT presentation, but risk increases during the acute phase after thrombotic event. Most seizures resolve during the first month, but epilepsy occurred in 15% of patients with CVT in the long run.

Long-Term Outcomes in Patients with Anemia And Cerebral Venous Thrombosis

2018 ◽  
Vol 29 (3) ◽  
pp. 463-468 ◽  
Author(s):  
Kai Liu ◽  
Bo Song ◽  
Yuan Gao ◽  
Lu Zhao ◽  
Hui Fang ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Cerebral Venous Thrombosis ◽  
Long Term Outcomes

A Single-Center Retrospective Evaluation of the Use of Oral Factor Xa Inhibitors in Patients With Cerebral Venous Thrombosis

2020 ◽  
pp. 106002802095274
Author(s):  
Marissa Powell ◽  
Kathryn Tremolet de Villers ◽  
Kerry Schwarz ◽  
David Case ◽  
Toby Trujillo
Keyword(s):  
Venous Thrombosis ◽  
Anticoagulant Therapy ◽  
Cerebral Venous Thrombosis ◽  
Factor Xa ◽  
Factor Xa Inhibitors ◽  
Factor Xa Inhibitor ◽  
Single Center ◽  
Persistent Symptoms ◽  
Secondary Outcomes

Background: Clinical practice guidelines recommend that cerebral venous thrombosis (CVT) be managed with long-term anticoagulant therapy using warfarin or low-molecular-weight heparin (LMWH) for 3 to 12 months. However, oral factor Xa inhibitors may offer preferable alternative treatment options for these patients. Objective: The primary objective was to determine the effectiveness and safety of rivaroxaban or apixaban compared with warfarin or enoxaparin as long-term anticoagulation therapy for patients with a new diagnosis of CVT. Methods: This was a single-center retrospective review of patients with newly diagnosed CVT who received acute and maintenance anticoagulation treatment. Study groups compared patients who received warfarin, enoxaparin, or an oral factor Xa inhibitor as their maintenance anticoagulant. The primary outcome was recurrent thrombotic events while on anticoagulation. Secondary outcomes included modified Rankin Scale, improved cerebral venous sinus opacification, duration of anticoagulant therapy, bleeding events during anticoagulant therapy, and adverse effects. Results: A total of 119 patients were included in the analysis: warfarin (89), enoxaparin (11), and oral factor Xa inhibitor (19). The risk of recurrent thrombotic events were 11.2%, 0%, and 10.5% in the warfarin, enoxaparin, and oral factor Xa inhibitor treatment groups, respectively ( P = 0.7635). There were no significant between-group differences observed regarding any of the secondary outcomes. Conclusions: Although the sample size is limited, these findings indicate that oral factor Xa inhibitors are a reasonable treatment option for patients with CVT. There was a trend toward more persistent symptoms in patients on warfarin, suggesting a potential improvement in recovery among patients that received an oral factor Xa inhibitor.

Sign in / Sign up

Export Citation Format

Share Document